Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM40H in Advanced Solid Tumors and Hematological Malignancies
NCT05549557Phase 1Unknown
- Sponsor
- ImmuneOnco
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- IgG Antibodies
01
Overview
Phase 1, open-label, single-arm trial of IMM40H in melanoma, nasopharyngeal carcinoma (NPC), thymoma and 10 more, sponsored by ImmuneOnco. Primary endpoint: Safety and tolerability of IMM40H at 28 days. Status: unknown.
02
Drugs
IMM40H
03
Conditions
melanomanasopharyngeal carcinoma (NPC)thymomarenal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05549557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549557.